Selected article for: "accessory protein and structural protein"
Author: Lovetrue, Bragi
Title: The AI-discovered Aetiology of COVID-19 and Rationale of the Irinotecan+ Etoposide Combination Therapy for Criti- cally Ill COVID-19 Patients
  • Cord-id: mqqji7tl
  • Document date: 2020_8_15
    • ID: mqqji7tl
    Snippet: We present the AI-discovered aetiology of COVID-19, based on a precise disease model of COVID-19 built under five weeks that best matches the epidemiological characteristics, transmission dynamics, clinical features, and biological properties of COVID-19 and con- sistently explains the rapidly expanding COVID-19 literature. We present that SARS-CoV- 2 implements a unique unbiased survival strategy of balancing viral replication with viral spread by increasing its dependence on (i) ACE2-expressin
    Document: We present the AI-discovered aetiology of COVID-19, based on a precise disease model of COVID-19 built under five weeks that best matches the epidemiological characteristics, transmission dynamics, clinical features, and biological properties of COVID-19 and con- sistently explains the rapidly expanding COVID-19 literature. We present that SARS-CoV- 2 implements a unique unbiased survival strategy of balancing viral replication with viral spread by increasing its dependence on (i) ACE2-expressing cells for viral entry and spread, (ii) PI3K signaling in ACE2-expressing cells for viral replication and egress, and (iii) viral- non-structural-and-accessory-protein-dependent immunomodulation to balance viral spread and viral replication. We further propose the combination of irinotecan (an in-market topoi- somerase I inhibitor) and etoposide (an in-market topoisomerase II inhibitor) could poten- tially be an exceptionally effective treatment to protect critically ill patients from death caused by COVID-19-specific cytokine storms triggered by sepsis, ARDS, and other fatal comorbidities.

    Search related documents:
    Co phrase search for related documents
    • accessory protein structural protein and acute respiratory syndrome: 1, 2, 3, 4
    • accessory structural and acute cardiac injury: 1
    • accessory structural and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accessory structural and adaptive immune cell: 1
    • accessory structural and adaptive immune response: 1
    • acute respiratory syndrome and adaptive immune cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adaptive mutation: 1, 2, 3, 4, 5
    • acute respiratory syndrome and liver cholangiocyte: 1
    • acute respiratory syndrome and lung elastance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and lung ii alveolar cell type: 1, 2, 3